AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 367136
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of isosorbide dinitrate
Trial: 30381248
Drug: Lisdexamfetamine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisdexamfetamine (100 mg)
Trial: 30381248
Drug: d-Amphetamine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-Amphetamine (40 mg)
Trial: 26888874
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) administration of parenteral nutrition (n = 59)
Trial: 26888874
Drug: Peripheral IV
RxNorm normalized name: Soluline 7-Day Peripheral IV Line Supply
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral IV administration of parenteral nutrition (n = 61)
Trial: 25462646
Drug: Multi-family group
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-family group therapy (MFGT) intervention (six sessions)
Trial: 24671340
Drug: nalmefene 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nalmefene 18 mg/day
Trial: 16203059
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of pneumococcal conjugate vaccine (PCV)
Trial: 12771523
Drug: Intravesical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical treatment with interferon‐a2b (IFN‐a2b); administered weekly for 2 months, then twice a month for 4 months, and monthly for 6 months.
Trial: 12771523
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no further treatment); 10 patients.
Trial: 11879269
Drug: Group psychosocial
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group psychosocial intervention (six weekly cognitive/behavioral meetings)
Trial: 9146780
Drug: Cisapride 5
RxNorm normalized name: cisapride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 5 mg three times daily
Trial: 11904788
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg three times daily
Trial: 339448
Drug: Twice-weekly continuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly continuation regimen of streptomycin plus isoniazid after 13 weeks of initial daily triple chemotherapy
Trial: 339448
Drug: Twice-weekly continuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly continuation regimen of streptomycin plus isoniazid after 6 weeks of initial daily triple chemotherapy
Trial: 339448
Drug: Once-weekly regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly regimen of streptomycin plus isoniazid after 13 weeks of initial daily triple chemotherapy
Trial: 339448
Drug: 12 months
RxNorm normalized name: Elecare HMO 0-12 Months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 months of chemotherapy
Trial: 339448
Drug: 18 months
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 18 months of chemotherapy
Trial: 20640848
Drug: Autologous platelet
RxNorm normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous platelet gel (APG) applied after prosthesis implantation
Trial: 19813467
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of clarithromycin suspension (500 mg)
Trial: 19813467
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of clarithromycin suspension (500 mg)
Trial: 17541852
Drug: Paroxetine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine treatment in females with poor metabolic status (PM)
Trial: 17541852
Drug: Paroxetine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine treatment in males with poor metabolic status (PM)
Trial: 17541852
Drug: Paroxetine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine treatment in females with extensive metabolic status (EM)
Trial: 17541852
Drug: Paroxetine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine treatment in males with extensive metabolic status (EM)
Trial: 12786918
Drug: Magnesium oxide
RxNorm normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium oxide (9 mg/kg per day by mouth divided 3 times a day with food)
Trial: 10925968
Drug: Celecoxib 25-400
RxNorm normalized name: celecoxib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 25-400 mg b.i.d.
Trial: 10925968
Drug: Nonspecific NSAIDs
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonspecific NSAIDs (naproxen 500 mg b.i.d., diclofenac 50 or 75 mg b.i.d., ibuprofen 800 mg t.i.d.)
Trial: 10925968
Drug: Celecoxib 100-400
RxNorm normalized name: celecoxib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 100-400 mg b.i.d. (long-term open-label trial)
Trial: 1346505
Drug: Zidovudine 400
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine 400 mg daily
Trial: 1346505
Drug: Zidovudine 800
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine 800 mg daily
Trial: 1346505
Drug: Zidovudine 1200
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine 1200 mg daily
Trial: 1346505
Drug: Zidovudine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (all doses)
Trial: 6593147
Drug: Amine fluoride
RxNorm normalized name: triethylene amine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amine fluoride gel (5 min once weekly)
Trial: 6593147
Drug: Fluoride-free dentifrice
RxNorm normalized name: potassium nitrate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoride-free dentifrice (twice daily)
Trial: 31570028
Drug: Dilapan-S with
RxNorm normalized name: S-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilapan-S with 200 mg oral mifepristone (study group)
Trial: 30728457
Drug: Azacitidine (given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azacitidine (given prior to therapy with idarubicin and etoposide)
Trial: 30728457
Drug: Azacitidine (given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azacitidine (given after therapy with idarubicin and etoposide)
Trial: 25313094
Drug: Inosine 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inosine 3 g/day
Trial: 17110281
Drug: TCH346 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCH346 0.5 mg
Trial: 17110281
Drug: TCH346 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCH346 2.5 mg
Trial: 17110281
Drug: TCH346 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCH346 10 mg
Trial: 17110281
Drug: TCH346 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCH346 (all doses)
Trial: 2871667
Drug: Celiprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol (100 mg oral dose, given 6 hours after symptom onset)
Trial: 31644731
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy for caregivers
Trial: 23739574
Drug: DEX (0.5‐1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX (0.5‐1.0 μg/kg load, 0.2‐0.6 μg×kg⁻¹×h⁻¹ for 24 hours)
Trial: 23739574
Drug: Propofol (0.5‐2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (0.5‐2.0 mg/kg load, 1‐3 mg×kg⁻¹×h⁻¹ for 72 hours)
Trial: 23739574
Drug: Pethidine and
RxNorm normalized name: pethidine and antispasmodics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine and other temporary medication (group C)
Trial: 22051828
Drug: Linfonex™ 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linfonex™ 1000 mg
Trial: 22051828
Drug: Cellcept™ 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cellcept™ 1000 mg
Trial: 16874422
Drug: Nickel sulphate
RxNorm normalized name: Nickel sulphate
DrugBank: Nickel sulfate (DB14180)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nickel sulphate patch test
Trial: 16874422
Drug: Negative fragrance
RxNorm normalized name: Myristica fragrans fruit
DrugBank: Myristica fragrans fruit (DB15544)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative fragrance patch test
Trial: 8094349
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg every 8 h for 7 days)
Trial: 3322097
Drug: Midazolam 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.15 mg.kg‐1, 0.25 mg.kg‐1, 0.30 mg.kg‐1, 0.35 mg.kg‐1, 0.40 mg.kg‐1 (open study)
Trial: 3322097
Drug: Midazolam 0.2
RxNorm normalized name: midazolam 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.2 mg.kg‐1 (double-blind study)
Trial: 29775954
Drug: Target group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target group with specific physical therapy techniques added to conventional protocol
Trial: 29775954
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with conventional physical therapy protocol
Trial: 29363217
Drug: Active placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active placebo tolterodine 1 mg
Trial: 25661312
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (further intravenous morphine only)
Trial: 23301896
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg ginseng twice daily for 3 months
Trial: 21129375
Drug: Peginterferon (half-dose)
RxNorm normalized name: peginterferon alfa-2a Injection [Pegasys]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon (half-dose)
Trial: 18351194
Drug: Patient-directed intervention
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-directed intervention (in subgroup with no aspirin use at baseline)
Trial: 18351194
Drug: Reminder-only (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reminder-only (in subgroup with no aspirin use at baseline)
Trial: 39585
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg propranolol and 100 mg metoprolol
Trial: 18316395
Drug: Moderate daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate daily alcohol consumption (16.4‐42.6 g ethanol/day)
Trial: 18316395
Drug: Moderate or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate or heavy alcohol drinkers (>or=42.7 g ethanol/day)
Trial: 16602254
Drug: HBO2 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HBO2 treatment at 2.4 atm abs pressure with 90 minutes of 100% oxygen breathing
Trial: 12963554
Drug: Gastric acid-lowering
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric acid-lowering medications (histamine receptor H2 antagonists or proton pump inhibitors)
Trial: 12963554
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not receiving gastric acid-lowering medications)
Trial: 3494005
Drug: Doses to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses to the prostate in excess of 7000 cGy
Trial: 3494005
Drug: Total dose
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total dose to the regional lymphatics (4400 to 5100 cGy)
Trial: 22499965
Drug: Oral Impact
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Impact for 5 days before surgery
Trial: 20045497
Drug: Statin (simvastatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin (simvastatin, moderate to high dose)
Trial: 17901413
Drug: Bosentan 62.5
RxNorm normalized name: bosentan 62.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan 62.5 mg twice daily for 4 weeks, increased to 125 mg twice daily thereafter for 12 months
Trial: 15486003
Drug: Remifentanil, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil, 1 microg kg(‐1) injected over 60 s, followed by infusion of 0.25 microg kg(‐1) min(‐1) for 10 min then 0.5 microg kg(‐1) min(‐1) for 10 min
Trial: 12202963
Drug: High-dose clonidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose clonidine (2.5 mg/kg)
Trial: 10489843
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (100 microg or 200 microg daily)
Trial: 1728438
Drug: Ro 42-5892
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 42-5892 (600 mg p.o.)
Trial: 6731326
Drug: Metoprolol (beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (beta 1-selective blocker), administered intravenously followed by oral treatment for 3 months.
Trial: 15987349
Drug: Prophylactic platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic platelet transfusion trigger level < 10 x 10(9) PLTs per L (T10; n = 79)
Trial: 15987349
Drug: Prophylactic platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic platelet transfusion trigger level < 30 x 10(9) PLTs per L (T30; n = 87)
Trial: 15987349
Drug: Prophylactic platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic platelet transfusion trigger level < 10 x 10(9) PLTs per L (T10)
Trial: 15987349
Drug: Prophylactic platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic platelet transfusion trigger level < 30 x 10(9) PLTs per L (T30)
Trial: 8768856
Drug: MK-386 (10-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-386 (10-100 mg)
Trial: 8768856
Drug: Finasteride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (5 mg) + MK-386 (25 mg)
Trial: 1725915
Drug: Hydrochlorothiazide (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (12.5 mg once daily, then 25 mg once daily, and finally 25 mg twice daily)
Trial: 1725915
Drug: Verapamil (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (120 mg once daily, then 240 mg once daily, and finally 240 mg twice daily)
Trial: 1725915
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hydrochlorothiazide and verapamil (25 mg and 240 mg once daily and twice daily)
Trial: 6789593
Drug: Thyrotrophin releasing
RxNorm normalized name: Thyrotrophin releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyrotrophin releasing hormone (TRH)
Trial: 30612463
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day Coenzyme Q10 and 500 mg/day L-carnitine for 8 weeks
Trial: 24433285
Drug: Febuxostat (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat (10 mg/day for weeks 1-4, 20 mg/day for weeks 5-8, 40 mg/day from week 9 to week 108)
Trial: 15589377
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 500 mg/day
Trial: 15589377
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 1000 mg/day
Trial: 2536288
Drug: Chemotherapy maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy maintenance with MACC regimen (38 subjects)
Trial: 2536288
Drug: Chemotherapy discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy discontinuation (36 subjects)
Trial: 23342337
Drug: Implant-retained overdenture
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implant-retained overdenture (IOD) group
Trial: 6370030
Drug: Chlorprothixene 1
RxNorm normalized name: chlorprothixene 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorprothixene 1 mg/kg i.m.
Trial: 6370030
Drug: Chlorprothixene 2
RxNorm normalized name: chlorprothixene 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorprothixene 2 mg/kg orally
Trial: 25096067
Drug: vemurafenib, 960
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vemurafenib, 960 mg orally twice daily
Trial: 25096067
Drug: dacarbazine, 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dacarbazine, 1,000 mg/m2 intravenously every 3 weeks
Trial: 11939810
Drug: 0.1% tazarotene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% tazarotene gel applied twice daily (T + T)
Trial: 11939810
Drug: 0.1% tazarotene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% tazarotene gel applied once daily and vehicle gel once daily (T + V)
Trial: 11939810
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle gel applied twice daily (V + V)
Trial: 2355823
Drug: Phosphate loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate loading (1000 mg of tribasic sodium phosphate, four times daily for 6 days)
Trial: 122406
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg haloperidol
Trial: 122406
Drug: Prolactin plus
RxNorm normalized name: prolactin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolactin plus luteinizing hormone
Trial: 30939483
Drug: SGLT2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT2 inhibitors (Canagliflozin, Empagliflozin, Dapagliflozin)
Trial: 23187044
Drug: Paraffin bath
RxNorm normalized name: Paraffin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paraffin bath therapy (5 times per week, for 3-week duration)
Trial: 23187044
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no paraffin bath therapy)
Trial: 22025157
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg orally once a day) + Placebo
Trial: 22025157
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg orally once a day) + R1507 (9 mg/kg weekly)
Trial: 22025157
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg orally once a day) + R1507 (16 mg/kg every 3 weeks)
Trial: 22025157
Drug: R1507 (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R1507 (9 mg/kg weekly)
Trial: 12045122
Drug: Prolastin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolastin (60 mg/kg) administered in four infusions at weekly intervals
Trial: 10213433
Drug: 3 microg/mL(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 microg/mL(‐1) of PPF and 0.5 ng/mL(‐1) of SUF in group I (GI)
Trial: 10213433
Drug: 3 microg/mL(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 microg/mL(‐1) of PPF and 1 ng/mL(‐1) of SUF in group II (GII)
Trial: 655282
Drug: Desipramine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (50 mg)
Trial: 29133320
Drug: Usual physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual physical therapy (Control group)
Trial: 19253234
Drug: High-dose isotretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose isotretinoin (>0.5 mg/kg per day)
Trial: 19253234
Drug: Low-dose isotretinoin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose isotretinoin (<0.5 mg/kg per day)
Trial: 15495821
Drug: Puerarin injection
RxNorm normalized name: PUERARIA MIRIFICA ROOT
DrugBank: Puerarin (DB12290)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Puerarin injection (500 mg per day for 2 weeks)
Trial: 11560455
Drug: bupropion, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupropion, 300 mg/d
Trial: 7522124
Drug: Postoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiation therapy
Trial: 9783890
Drug: High dose-volume
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose-volume group
Trial: 3169110
Drug: Cicloprolol 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cicloprolol 25 mg
Trial: 2904826
Drug: Cicloprolol 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cicloprolol 50 mg
Trial: 2904826
Drug: Cicloprolol 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cicloprolol 100 mg
Trial: 3169110
Drug: Cicloprolol (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cicloprolol (up to 200 mg)
Trial: 3169110
Drug: Prenalterol 50
RxNorm normalized name: prenalterol
DrugBank: Prenalterol (DB13777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenalterol 50 mg
Trial: 26265125
Drug: Mannitol treatment
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mannitol treatment (n=1533)
Trial: 26265125
Drug: Nonmannitol treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonmannitol treatment (n=993)